Unverified
Investigating claim Trump got exclusive access to potent obesity drug retatrutide
The claim that Trump had exclusive access to the obesity drug retatrutide lacks sufficient evidence from reliable sources.
Key points
- No credible reports or official statements confirm Trump's exclusive access to retatrutide.
- Retatrutide is still in clinical trials and has not been approved for public use.
- Information about Trump’s medical treatments is generally kept private.
Explanation
The claim that Donald Trump had exclusive access to the obesity drug retatrutide lacks supporting evidence. Retatrutide, which targets ghrelin receptors, is currently in clinical trials and has not been approved for public use. Given its experimental nature, it would be highly unusual for such a drug to be made available exclusively to any individual without formal approval processes. Additionally, Trump’s medical treatments are typically kept private, making it difficult to verify claims about his access to specific medications.